永顺生物(839729) - 2023 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 20,894,809.49, representing a growth of 20.58% year-on-year[9] - Operating revenue for the first quarter of 2023 was CNY 81,091,529.35, up 3.07% from the same period last year[9] - Total operating revenue for Q1 2023 reached ¥81,091,529.35, an increase of 3.6% compared to ¥78,677,625.48 in Q1 2022[58] - Total profit reached CNY 23,799,155.91, up from CNY 19,841,045.10, indicating a growth of approximately 19.7%[63] - Operating profit slightly decreased to CNY 18,864,589.14 from CNY 19,833,123.92, a decline of about 4.9%[63] - Basic and diluted earnings per share for Q1 2023 were both ¥0.08, up from ¥0.06 in Q1 2022[60] - The company reported a significant increase in interest income to CNY 1,687,597.44 from CNY 1,188,495.23, representing a growth of approximately 42%[63] - Net profit rose to CNY 20,889,136.99, compared to CNY 17,322,251.00, marking an increase of about 20.5% year-over-year[64] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 14,410,166.78, a decrease of 9283.03% compared to the previous year[13] - Cash flow from investment activities showed a net outflow of CNY 50,994,104.00, a significant increase of 539.85% compared to the previous year[13] - The net cash flow from operating activities was -14,415,846.86, a significant decrease compared to 149,774.03 from the previous period, indicating a decline in operational efficiency[68] - The total cash outflow from operating activities was 76,338,631.09, which is an increase from 61,643,415.40 in the previous period, indicating rising operational costs[68] - The company faced a net cash outflow of 50,994,104.00 from investing activities, highlighting a focus on capital expenditures despite the negative cash flow[68] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 881,274,401.64, an increase of 1.42% compared to the end of the previous year[9] - The total liabilities to assets ratio remained stable at 19.30% for both the parent and consolidated entities[9] - Total liabilities decreased to ¥170,113,880.59 from ¥172,771,172.59, a reduction of approximately 1.53%[52] - Total equity attributable to shareholders rose to ¥711,160,521.05 from ¥696,141,073.57, an increase of approximately 2.16%[52] - Total non-current assets decreased to ¥244,289,161.03 from ¥251,674,448.53, a decline of about 2.94%[51] - Cash and cash equivalents decreased to ¥257,183,751.02 from ¥293,867,101.54, a decline of about 12.5%[50] Shareholder Information - The total number of shareholders as of the report date was 3,426[17] - The company reported a total share repurchase of 3,055,980 shares, accounting for 1.12% of the total share capital, with a total expenditure of approximately ¥24.60 million, representing 57.09% of the planned repurchase fund limit[31] - The company has a significant shareholder structure, with the largest shareholder holding 39.06% and the second-largest holding 19.71%[22] - The company has successfully implemented its share repurchase plan, achieving 84.89% of the planned repurchase quantity[31] Legal and Compliance - The company is involved in two non-significant lawsuits with a total claim amount of ¥4.98 million, currently in the execution phase[27] - The company has not reported any significant external guarantees or loans during the reporting period[26] - The company has no reported cases of asset seizure, freezing, or other significant legal issues during the reporting period[26] - Major shareholders have signed commitments to avoid competition, which were fulfilled without any violations during the reporting period[33] - Commitments to avoid fund occupation by major shareholders were adhered to without any breaches in the reporting period[34] - The company has maintained compliance with commitments to regulate related party transactions, with no violations reported[35] Research and Development - Research and development expenses for Q1 2023 were ¥6,647,428.05, up from ¥5,504,816.75 in Q1 2022, indicating an increase of 20.7%[59] - R&D expenses increased to CNY 6,647,428.05 from CNY 5,504,816.75, reflecting a growth of approximately 20.7%[63]